Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million
Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million
Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta
DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa)
2024 Financial Guidance
For the full year 2024, the company expects:
- Total revenue to be in the range of $530 million to $550 million
- Crysvita revenue to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
- Dojolvi revenue to be in the range of $75 million to $80 million
- Net Cash Used in Operations of around $400 million
Conference Call and Webcast Information
Ultragenyx will host a conference call today, Tuesday, November 5, 2024, at 2 p.m. PT/5 p.m. ET to discuss the third quarter 2024 financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for one year.
Ultragenyx will host a conference call today, Tuesday, November 5, 2024, at 2 p.m. PT/5 p.m. ET to discuss the third quarter 2024 financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for one year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.